Phase 3 clinical trials for the much-anticipated Oxford COVID-19 vaccine are set to begin in the United States Tuesday, with participants in Madison, Wisconsin rolling up their sleeves for the injection.
The University of Wisconsin is one of dozens of test sites in the U.S. for the vaccine candidate, made by AstraZeneca in partnership with the U.K.’s University of Oxford. Tuesday’s trial will mark the start of the third phase 3 trial in the U.S. for a COVID-19 vaccine, following Moderna and Pfizer.
The beginning of the trial comes as President Donald Trump is exerting pressure to fast-track research on a vaccine, alluding to some sort of approval before the election in early November.
But Dr. William Hartman, an assistant professor of anesthesiology at UW Health and the University of Wisconsin-Madison School of Medicine and Public Health, doesn’t expect preliminary data until at least Thanksgiving.